You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Investigational Drug Information for Emodepside


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Emodepside?

Emodepside is an investigational drug.

There have been 6 clinical trials for Emodepside. The most recent clinical trial was a Phase 1 trial, which was initiated on August 30th 2021.

The most common disease conditions in clinical trials are Hookworm Infections, Ancylostomiasis, and Filariasis. The leading clinical trial sponsors are Bayer, Drugs for Neglected Diseases, and Bill and Melinda Gates Foundation.

There are two hundred and six US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Emodepside
TitleSponsorPhase
Efficacy and Safety of Emodepside in Adults Infected With HookwormPublic Health Laboratory Ivo de CarneriPhase 2
Efficacy and Safety of Emodepside in Adults Infected With HookwormJennifer KeiserPhase 2
Emodepside Phase II Trial for Treatment of OnchocerciasisBayerPhase 2

See all Emodepside clinical trials

Clinical Trial Summary for Emodepside

Top disease conditions for Emodepside
Top clinical trial sponsors for Emodepside

See all Emodepside clinical trials

US Patents for Emodepside

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Emodepside ⤷  Try for Free Six-membered C--N-bonded aryl sulphide and aryl sulphoxide derivatives as pesticides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (Monheim am Rhein, DE) ⤷  Try for Free
Emodepside ⤷  Try for Free Anthelmintic compounds MERIAL INC. (Duluth, GA) ⤷  Try for Free
Emodepside ⤷  Try for Free Pyrazolopyridine sulfonamides as nematicides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (Monheim am Rhein, DE) ⤷  Try for Free
Emodepside ⤷  Try for Free Anthelmintic depsipeptide compounds MERIAL, INC. (Duluth, GA) ⤷  Try for Free
Emodepside ⤷  Try for Free 2-(het)aryl-substituted fused bicyclic heterocycle derivatives as pesticides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (Monheim am Rhein, DE) ⤷  Try for Free
Emodepside ⤷  Try for Free Substituted guanidines as fungicides Nippon Soda Co., Ltd. (Tokyo, JP) ⤷  Try for Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Emodepside

Drugname Country Document Number Estimated Expiration Related US Patent
Emodepside Australia AU2015286634 2034-07-11 ⤷  Try for Free
Emodepside Brazil BR112017000398 2034-07-11 ⤷  Try for Free
Emodepside China CN106659720 2034-07-11 ⤷  Try for Free
Emodepside European Patent Office EP3177291 2034-07-11 ⤷  Try for Free
Emodepside Japan JP2017519802 2034-07-11 ⤷  Try for Free
Emodepside World Intellectual Property Organization (WIPO) WO2016005576 2034-07-11 ⤷  Try for Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Emodepside: A Promising Drug Candidate in the Fight Against Parasitic Worm Infections

Last updated: January 2, 2025

Introduction

Emodepside, originally developed as an antihelminthic veterinary drug for cats and dogs, is now being evaluated for its potential as a treatment for parasitic worm infections in humans. This article provides an update on the development of emodepside and its market projections.

Background and Origin

Emodepside was first developed by the Japanese pharmaceutical company Astellas and later commercialized by Bayer Animal Health. The Drugs for Neglected Diseases initiative (DNDi), in collaboration with Bayer AG, is currently advancing the clinical development of emodepside as a potential anti-parasitic macrofilaricidal treatment for onchocerciasis and other parasitic infections[1].

Current Phase of Drug Development

As of the latest updates, emodepside has successfully completed first-in-human Phase I studies, including both single ascending dose and multiple ascending dose studies in healthy volunteers in 2017 and 2018, respectively. These studies demonstrated that emodepside is orally bioavailable, and a tablet formulation has been developed for potential commercial use[1].

Phase II Clinical Trials

The Phase II proof-of-concept clinical trial, initiated in 2021, aims to investigate the safety and efficacy of emodepside in patients infected with Onchocerca volvulus. The trial is being conducted in Ghana and the Democratic Republic of the Congo. By April 2023, recruitment for the Phase II trial was finalized, and all study participants had completed treatment. Initial findings from this trial are expected to be released in the third quarter of 2024[1].

Efficacy and Safety Profile

Recent studies have confirmed the efficacy and safety of emodepside in treating parasitic worm infections. A Phase 2b trial published in The Lancet showed that emodepside had a strong efficacy and safety profile, particularly in treating hookworm infections. The study involved 293 participants infected with hookworms and demonstrated a cure rate of 96.6% with a single 30 mg dose of emodepside, compared to an 81.2% cure rate with the standard 400 mg dose of albendazole[3].

Notable Efficacy

Emodepside has shown notable efficacy in individuals with Trichuris trichiura and hookworm infections, positioning it as a promising candidate for pan-nematode treatment. This efficacy, combined with its safety profile, makes emodepside a potential game changer in the fight against helminthiasis[1][3].

Market Projections

The anthelmintic drugs market, which includes emodepside, is expected to grow significantly in the coming years. Here are some key market projections:

Market Size and Growth

The anthelmintic drugs market was valued at USD 2.62 billion in 2024 and is projected to reach USD 3.52 billion by 2031, growing at a CAGR of 4.13% from 2024 to 2031[2].

Segment Analysis

The market is categorized based on application (including benzimidazoles, macrocyclic lactones, pyrantel, and emodepside) and product (including veterinary medicine, parasitic worm treatment, human helminthiasis treatment, and preventive healthcare). The report also analyzes trends and factors influencing the market across various geographical regions[5].

Future Development and Trials

Following the positive outcomes of the Phase II trials, emodepside is expected to proceed to Phase III trials. These trials are planned to start in 2025 on Pemba Island and the Philippines, further evaluating the safety, long-term effectiveness, and optimal use of emodepside in treating parasitic worm infections[3].

Likelihood of Approval

GlobalData's report indicates that Phase II drugs for ancylostomiasis (hookworm infections) have a 100% phase transition success rate (PTSR) benchmark for progressing into Phase III. This suggests a high likelihood of approval for emodepside as it moves through the clinical trial phases[4].

Conclusion

Emodepside is a promising drug candidate with significant potential in the treatment of parasitic worm infections. Its strong efficacy and safety profile, as demonstrated in recent clinical trials, position it as a critical treatment option for both individual cases and as part of global deworming efforts. As the drug progresses through its development stages, it is likely to play a major role in the growing anthelmintic drugs market.

Key Takeaways

  • Emodepside is being developed for human use after initial success as a veterinary drug.
  • Phase II clinical trials have shown high efficacy and safety in treating hookworm and other parasitic infections.
  • The drug is expected to proceed to Phase III trials in 2025.
  • The anthelmintic drugs market is projected to grow significantly, with emodepside contributing to this growth.
  • Emodepside has a high likelihood of approval based on historical drug development data.

FAQs

What is emodepside and how is it being developed?

Emodepside is an antihelminthic drug originally developed for veterinary use. It is now being evaluated for human use by DNDi in collaboration with Bayer AG to treat parasitic worm infections such as onchocerciasis and hookworm infections.

What are the current stages of emodepside's clinical development?

Emodepside has completed Phase I studies and is currently in Phase II clinical trials to investigate its safety and efficacy in patients infected with Onchocerca volvulus. Phase III trials are planned to start in 2025.

How effective is emodepside in treating parasitic worm infections?

Recent studies have shown that emodepside has a high efficacy in treating hookworm infections, with a cure rate of 96.6% compared to 81.2% with the standard treatment albendazole.

What is the market projection for the anthelmintic drugs market?

The anthelmintic drugs market is projected to grow from USD 2.62 billion in 2024 to USD 3.52 billion by 2031, at a CAGR of 4.13%.

What are the next steps in the development of emodepside?

Following the positive outcomes of Phase II trials, emodepside is expected to proceed to Phase III trials in 2025, which will be conducted on Pemba Island and the Philippines.

Sources

  1. DNDi: Emodepside - DNDi
  2. Verified Market Research: In-Depth Industry Outlook: Anthelmintic Drugs Market Size, Forecast
  3. Swiss TPH: New Study Confirms Efficacy of Emodepside Against Parasitic Worm Infections
  4. Pharmaceutical Technology: Emodepside by Bayer for Ancylostomiasis (Hookworm Infections)
  5. Market Research Intellect: Anthelmintic Drugs Market Size, Share & Growth Factors | Forecast

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.